Antibiotic prophylaxis in COPD: Why, when, and for whom?

Pulmonary Pharmacology and Therapeutics

Volumn 32, Issue , 2015, Pages 119-123

  Miravitlles, Marc ^a,b   Anzueto, Antonio ^c,d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Antibiotics; Bronchial colonization; COPD; Macrolides; Prophylaxis; Quinolones

Indexed keywords

ANTIBIOTIC AGENT; MACROLIDE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; PNEUMONIA; PRIORITY JOURNAL; BACTERIAL INFECTIONS; COMPLICATION; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME FACTORS;

EID: 84930514770     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.05.002     Document Type: Article

References (42)

1. Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012, 379:1341-1351.
2. Staykova T, Black PN, Chacko EE, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Rev;CD004105. Published online: 21 Jan 2009. DOI: . http://dx.doi.org/10.1002/14651858.
3. Vestbo J., Hurd S.S., Agusti A.G., Jones P.W., Vogelmeier C., Anzueto A. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013, 187:347-365.
4. Hurst J.R., Vestbo J., Anzeto A., Locantore N., Müllerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
5. Garcha D.S., Thurston S.J., Patel A.R.C., Mackay A.J., Goldring J.J.P., Donaldson G.C., et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012, 67:1075-1080.
6. Singh S., Amin A.V., Loke Y.K. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. J Am Med Assoc 2009, 169:219-229.
7. Bafadhel M., McKenna S., Terry S., Mistry V., Pancholi M., Venge P., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012, 186:48-55.
8. Miravitlles M., Soler-Cataluña J.J., Calle M., Soriano J. Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice. Eur Respir J 2013, 41:1252-1256.
9. Matkovic Z., Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype?. Respir Med 2013, 107:10-22.
10. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365.
11. Miravitlles M., Marin A., Monsó E., Vilà S., de la Roza C., Hervás R., et al. Colour of sputum is a marker of bacterial colonization in COPD. Respir Res 2010, 11:58.
12. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1090-1095.
13. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010, 35:1209-1215.
14. Yamaya M., Azuma A., Takizawa H., Kadota J.I., Tamaoki J., Kudoh S. Macrolide effects on the prevention of COPD exacerbations. Eur Respir J 2012, 40:485-494.
15. Suzuki T., Yanai M., Yamaya M., Satoh-Nakagawa T., Sekizawa K., Ishida S., et al. Erythromycin and common cold in COPD. Chest 2001, 120:730-733.
16. Seemungal T.A., Wilkinson T.M., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147.
17. Blasi F., Bonardi D., Aliberti S., Tarsia P., Confalonieri M., Amir O., et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010, 23:200-207.
18. He Z.-Y., Ou L.-M., Zhang J.-Q., Bai J., Liu G.-N., Li M.-H., et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010, 80:445-452.
19. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A.D., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
20. Pomares X., Montón C., Espasa M., Casabon J., Monsó E., Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 2011, 6:449-456.
21. Sethi S., Jones P.W., Theron M.S., Miravitlles M., Rubinstein E., Wedzicha J.A., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010, 11:10.
22. Gómez J., Baños V., Simarro E., Lorenzo Cruz M., Ruiz Gomez J., Latour J., et al. studio prospective y comparative (1994-1998) sobre la influencia del tratamiento corto profiláctico con azitromicina en pacientes con EPOC evolucionada. Rev Esp Quimioter 2000, 13:379-383.
23. O'Reilly P.J., Jackson P.L., Wells J.M., Dransfield M.T., Scanlon P.D., Ballock J.E. Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open 2013, 3:e004140.
24. Serisier D.J. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013, 1:262-274.
25. Albert R.K. Response to: should we give long-term macrolide therapy for COPD?. Thorax 2013, 68:967.
26. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
27. Rodvold K.A. Clinical safety profile of newer fluoroquinolones. Infect Med 1999, 16(Suppl. F):41-53.
28. Morganroth J., Di Marco J.P., Anzueto A., Niederman M.S., Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community- acquired pneumonia. Chest 2005, 128:3398-3406. the CAPRIE Study Group.
29. Bafadhel M., McKenna S., Terry S., Mistry V., Reid C., Haldar P., et al. Acute exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011, 184:662-671.
30. Miravitlles M., Anzueto A. Antibiotics for acute and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013, 188:1052-1057.
31. Rabe K.F., Fabbri L.M., Vogelmeier C., Kögler H., Schnmidt H., Beeh K.M., et al. Seasonal distribution of COPD exacerbations in the prevention of exacerbations with tiotropium in COPD trial. Chest 2013, 143:711-719.
32. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012, 48:247-257.
33. Miravitlles M. Long-term antibiotics in COPD: more benefit than harm?. Prim Care Respir J 2013, 22:261-270.
34. Spagnolo P., Fabbri L.M., Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J 2013, 42:239-251.
35. Wilson R., Sethi S., Anzueto A., Miravitlles M. Use of antibiotics in COPD exacerbations: from treatment to prevention. J Infect 2013, 67:497-515.
36. Martínez-García F., Soler-Cataluña J.J., Donat Y., Catalán P., Agramunt M., Ballestin V., et al. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Chest 2011, 140:1130-1137.
37. Patel I.S., Vlahos I., Wilkinson T.M.A., Lloyd-Owen S.J., Donaldson G.C., Wilks M., et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170:400-407.
38. O'Brien C., Guest P.J., Hill S.L., Stockley R.A. Physiological and radiological characterization of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000, 55:635-642.
39. Almagro P., Salvadó M., García-Vidal C., Rodríguez-Carballeira M., Cuchi E., Torres J., et al. Pseudomonas aeruginosa and mortality after hospital admission for chronic obstructive pulmonary disease. Respiration 2012, 84:36-43.
40. Renom F., Yañez A., Garau M., Rubí M., Centeno M.J., Gorriz M.T., et al. Prognosis of COPD patients requiring frequent hospitalization: role of airway infection. Respir Med 2010, 104:840-848.
41. James G.D., Petersen I., Nazareth I., Wedzicha J.A., Donaldson G.C. Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim Care Respir J 2013, 22:271-277.
42. Dal Negro R., Micheletto C., Tognella S., Visconti M., Turati C. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 2008, 25:1019-1103.